Ameritas Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$48.1K Sell
870
-148
-15% -$7.99K ﹤0.01% 1276
2026
Q2
$55.5K Buy
+1,018
New +$53.7K ﹤0.01% 1232
2025
Q4
– Sell
-143
Closed -$9.27K – 1169
2025
Q3
$9.27K Hold
143
– – ﹤0.01% 1688
2025
Q2
$6.96K Buy
+143
New +$5.53K ﹤0.01% 2144
2023
Q2
– Sell
-300
Closed -$14.2K – 946
2023
Q1
$14.2K Buy
+300
New +$14.6K ﹤0.01% 1777
2021
Q2
– Sell
-242
Closed -$29.5K – 1001
2021
Q1
$29.5K Buy
+242
New +$36.5K ﹤0.01% 1132

Other funds holding CRSP

Ameritas Advisory Services's CRSP Position: Q3 2026 in Review

Ameritas Advisory Services reduced its CRISPR Therapeutics (CRSP) stake by 15% in Q3 2026, selling an estimated $7.99K and leaving 870 shares worth $48.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1276.

Ameritas Advisory Services first reported a position in CRSP in Q1 2021 and has held it in 6 quarters since. The position peaked at $55.5K in Q2 2026. 503 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Ameritas Advisory Services held 870 shares of CRISPR Therapeutics worth $48.1K as of Q3 2026.
  • Ameritas Advisory Services sold 148 CRISPR Therapeutics shares in Q3 2026, an estimated $7.99K.
  • CRISPR Therapeutics made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q3 2026, its #1276 holding.
  • Ameritas Advisory Services first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Ameritas Advisory Services's CRISPR Therapeutics position peaked at $55.5K in Q2 2026.
  • 503 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Ameritas Advisory Services's 13F filing for Q3 2026, filed 12 Nov 2026.